Latest Breaking News On - Surface oncology - Page 3 : vimarsana.com

Why Coherus Biosciences Stock Dropped Today

Coherus missed estimates for the third quarter and lowered its full-year outlook.

Udenyca onbodyCoherus biosciencesJunshi biosciencesDenny lanfearDrug administrationShanghai junshiSurface oncology

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

– Net revenue rose 27% from prior quarter to $74.6 million –– CIMERLI® net sales increased 50% to $40 million compared to prior quarter –– LOQTORZI™ now approved with launch planned for.

Junshi biosciencesJami taylorJodi sieversCoherus biosciencesDenny lanfearMeeting of societyAmgen incDrug administrationSurface oncology incInternational conference on molecularAbbvie incExchange commission onCorporate communicationsCoherus biosciences incExchange commissionGenentech inc

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody.

San diegoUnited statesSan diego convention centerCoherus biosciencesJami taylorJodi sieversTheresa lavalleeExchange commissionVp corporate communicationsCoherus biosciences incDrug administrationAnnual meetingDaylight timeExhibit hallsSan diego conventionSurface oncology

Zenocutuzumab Generates Durable Responses in Advanced NRG1+ NSCLC

Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial.

Memorial sloan kettering cancer centerNew yorkUnited statesAlison schramBeigene springworksUs food drug administrationRelay therapeuticsBlueprint bioFlagship pioneeringRedona therapeuticsBlack diamond therapeuticsElevation oncologyNorthern biologicsRepare therapeuticsRevolution medicinesSurface oncology

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJudy steckerJunshi biosciencesDenny lanfearRuihua xuZhi liCoherus biosciencescoherusJodi sieversEndocrinopathiesadrenal insufficiencyJunshi bioscienceSolutions coherusShanghai junshi biosciences co ltdHospital cancer centerDrug administrationExchange commissionVp corporate communications